U.S. firm Epix Pharmaceuticals said Thursday it has begun a clinical trial of its drug to treat major depressive disorder. The company’s phase 2b trial will enroll about 330 patients with a primary diagnosis of MDD with concurrent anxiety. Read more…

CHARLESTON, S.C., March 23 /PRNewswire/ — Res Read more…

This entry was posted on Saturday, March 31st, 2007 at 10:30 am and is filed under Anxiety Depression. You can follow any responses to this entry through the RSS 2.0 feed. You can leave a response, or trackback from your own site.